Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
· manilatimes.net
FORTIFY, a Phase 1b indication expansion trial of PLN-101095,
FORTIFY, a Phase 1b indication expansion trial of PLN-101095,
experiencing strong enrollment
Appointed seasoned oncology drug development leaders
Flavia Bore...